All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
4 warning events since 2017; the latest 2026-06-08.
From the record
aTyr Pharma, Inc.'s filings since 2017 show 4 warning events: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2026-06-08) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-12.5% a year over 7 filed years; profitable in 0 of 7.
From the record
aTyr Pharma, Inc.'s 7 filed years say what it did: revenue went from $422 thousand in fiscal 2019 to $190 thousand in fiscal 2025, down 12.5% a year; it rose in 1 of 5 years; the deepest fall was 100% from fiscal 2020 to fiscal 2021; net income was positive in 0 of 7 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 2.9/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: aTyr Pharma, Inc.'s shareholder treatment is put at 2.9 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 29% of 146 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -110%: lost 110¢ per shareholder dollar. Leverage 27%: owes 27¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, aTyr Pharma, Inc. lost about 110 cents for every dollar of shareholders' money. Leverage: it owed about 27 cents per dollar of assets, and net share issuance: its share count grew 25.2% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 6% of 102 in its family; net margin -39009.5%.
From the record
aTyr Pharma, Inc.'s standing among 102 graded names in its industry family: revenue of $190 thousand in fiscal 2025 ranks in the bottom 12% by size; a net margin of -39009.5% ranks in the bottom 6%; revenue growth of -73.6% a year over the last 3 filed years ranks in the bottom 2% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 18% of 110 in its family for leadership; chief executive since 2017.
From the record
aTyr Pharma, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Shukla, Sanjay (President and CEO, as filed), filing under that title since 2017-11-03, 9 years (top 13% of its family); the 10 officers and directors filing in the last fifteen months have been on the record a median of 7.8 years (top 14%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 10 people in charge now (top 26%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 39% of 92 in its family for room to expand.
From the record
aTyr Pharma, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $11 million against no long-term debt tagged leaves 11.6% of its assets as net cash, bottom 17% of its family; cash from operations less capital spending is -32664.7% of revenue (bottom 4%); research spending of 31694.2% of revenue (top 4%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 31% of 100 in its family for growth drivers.
From the record
aTyr Pharma, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -73.6% a year over the last three filed years against -12.5% over all 7, slowing (bottom 13% of its family); the newest year grew -19.2% (bottom 21%); research spending grew 12% a year (top 27%); capital spending grew -63.9% a year (bottom 18%) (its annual reports). aTyr Pharma, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 38% of 72 in its family for expectations against reality.
From the record
aTyr Pharma, Inc.'s newest year against its own record: revenue of $190 thousand in fiscal 2025 came in 436.8% above the $35 thousand its prior three years' pace pointed to (top 8% of its family); net income of $74 million against a prior three-year average of $53 million (bottom 19%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 3%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made